RESUMEN
Objetivo: Detectar y notificar casos de suicidios o intentos de suicidios y alucinaciones en pacientes tratados con hidroxicloroquina para la enfermedad por Coronavirus 2019.Material y método: Estudio descriptivo retrospectivo de todos los pacientes tratados con hidroxicloroquina en los 40 días previos al suceso y que cumplían: suicidio consumado, psicosis aguda con intento de suicidio y comportamiento psicótico y agresividad con daño a terceros. Se excluyeron pacientes con situación previa de depresión, intento o plan organizado de suicidio, abuso de alcohol, falta de pensamiento racional o carencia de apoyo social. Para establecer el grado de asociación entre la sospecha de reacción adversa e hidroxicloroquina, se utilizó el algoritmo Karch y Lasagna modificado.Resultados: Se detectaron cinco casos graves de trastornos neuropsiquiátricos posiblemente relacionados con hidroxicloroquina: suicidio consumado (tres), crisis de psicosis aguda con intento de suicidio (uno) y comportamiento psicótico y agresividad con daño a terceros (uno); los dos últimos se recuperaron tras la retirada del medicamento. Todos eran varones, con edades comprendidas entre los 26-85 años. Las reacciones adversas de tipo psiquiátrico aparecieron entre los 2-5 días tras el inicio. Ninguno tenía antecedentes psiquiátricos previos, y todos se encontraban tranquilos, colaboradores y sin síntomas depresivos durante la hospitalización.Conclusión: La evidencia en otras patologías sugiere un aumento potencial de síntomas como ansiedad, ideación suicida y alucinaciones que pueden provocar agresiones o suicidio con la exposición a hidroxicloroquina, por lo que sería necesario generar evidencia del uso de hidroxicloroquina en esta situación actual de pandemia por la COVID-19 y en condiciones diferentes a las autorizadas. (AU)
Objective: This paper aims to detect and report suicide cases or suicide attempts and hallucinations during the emergency use of hydroxychloroquine for the treatment of Coronavirus Disease 2019.Methods: It was a retrospective descriptive study in which patients treated with hydroxychloroquine 40 days before the event were included: completed suicide, acute psychosis with suicide attempt and psychotic behavior and aggressiveness with harm to third parties. Patients with a previous situation of depression, attempted or organized suicide plan, alcohol abuse and lack of rational thought or social support were excluded. To establish the degree of association between suspected adverse drug reaction and hydroxychloroquine, the modified version of the algorithm proposed by Karch and Lasagna was used.Results: There were five case reports neuropsychiatric adverse events associated with the use of hydroxychloroquine: completed suicide (three); acute psychosis crisis with suicide attempt (one) and psychotic behavior and aggressiveness with harm to third parties (one), which recovered after withdrawal of hydroxychloroquine. All of them were male, with age ranged between 26-85 years. Psychiatric-type adverse reactions appeared between 2-5 days after initiating therapy. None had a prior psychiatric history, and all were calm, cooperative, and without depressive symptoms during hospitalization.Conclusion: Evidence in other pathologies suggests a potential increase in symptoms such as anxiety, suicidal ideation and hallucinations that can cause aggression or suicide with exposure to hydroxychloroquine, so others studies are needed in this current situation of pandemic by COVID-19 and unapproved use of hydroxychloroquine. (AU)
Asunto(s)
Humanos , Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo , Hidroxicloroquina , Alucinaciones , Suicidio , Infecciones por Coronavirus/epidemiología , Seguridad , TerapéuticaRESUMEN
INTRODUCTION: The oral route is the most convenient way of administering medication, although it may not be safe. Dysphagia is one of the factors rendering difficult a proper feeding and administration of medication. OBJECTIVES: to improve the administration of oral medication in patients with dysphagia by changing the pharmaceutical formulation of the principles prescribed to tolerable textures. METHODS: Pilot project for the application of a dysphagia protocol that included the patients admitted to the Internal Medicine Unit at Los Montalvos Center for 4 months. After detecting the suspicion of dysphagia, a dysphagia-viscosity test was applied to know the tolerated textures. Then, the pharmaceutical formulations were adapted and the manipulation instructions for the drugs were indicated for their proper administration. RESULTS: 23 out of 627 admitted patients were included, with a mean age of 85 years (σ±7.4). The pathologies implicated in dysphagia were: dementia (65.2%); cerebrovascular disease (30.4%), and Parkinson's disease (4.4%). The best texture for drug intake was a "pudding" in 48.0%. 43 active ingredients were reviewed and 134 interventions were performed: in 41% of the cases, swallowing was made easier by mixing the drug with the food and in 59% water and a thickener were used. 94% of the recommendations were considered to be appropriate. CONCLUSION: the adaptation of the pharmaceutical formulations to the degree of dysphagia impacts on the improvement of healthcare quality by implementing safety in drug prescription and administration processes.
Asunto(s)
Administración Oral , Trastornos de Deglución/diagnóstico , Trastornos de Deglución/epidemiología , Anciano , Anciano de 80 o más Años , Trastornos Cerebrovasculares/complicaciones , Trastornos Cerebrovasculares/epidemiología , Química Farmacéutica , Protocolos Clínicos , Deglución , Trastornos de Deglución/complicaciones , Demencia/complicaciones , Demencia/epidemiología , Femenino , Guías como Asunto , Estado de Salud , Hospitalización , Hospitales , Humanos , Pacientes Internos , Medicina Interna , Masculino , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/epidemiología , Proyectos Piloto , ViscosidadRESUMEN
Introducción: La vía oral es la forma de administrar medicación más cómoda, pero puede no ser segura. La disfagia es uno de los factores que dificulta la correcta alimentación y administración de la medicación. Objetivos: La mejora de la administración de la medicación oral en pacientes con disfagia, a través de la adecuación de la forma farmacéutica de los principios prescritos a las texturas toleradas. Métodos: Proyecto piloto de aplicación de un protocolo de disfagia, donde se incluyeron los pacientes ingresados en el Servicio de Medicina Interna-Los Montalvos durante 4 meses. Tras detectarse la sospecha de disfagia, se aplicaba un test de disfagia-viscosidad para conocer las texturas toleradas. Posteriormente se adecuaban las formas farmacéuticas y se indicaban las normas de manipulación de los fármacos para su correcta administración. Resultados: De los 627 pacientes ingresados se incluyeron 23 pacientes, con edad media de 85 años (σ ± 7,4). Las patologías implicadas en la disfagia fueron: demencia (65,2%); enfermedad cerebrovascular (30,4%) y enfermedad de Parkinson (4,4%). La textura óptima para la ingesta fue "pudin" en el 48,0%. Se revisaron 43 principios activos y se realizaron 134 intervenciones: En el 41% de ellas se facilitó la deglución mezclando el fármaco con los alimentos y en el 59% se utilizó la adición de agua y espesante. El 94% de las recomendaciones se consideraron adecuadas. Conclusión: La adecuación de las formas farmacéuticas al grado de disfagia repercute en la mejora de la calidad asistencial implementando la seguridad en los procesos de prescripción y administración de fármacos (AU)
Introduction: The oral route is the most convenient way of administering medication, although it may not be safe. Dysphagia is one of the factors rendering difficult a proper feeding and administration of medication. Objectives: to improve the administration of oral medication in patients with dysphagia by changing the pharmaceutical formulation of the principles prescribed to tolerable textures. Methods: Pilot project for the application of a dysphagia protocol that included the patients admitted to the Internal Medicine Unit at Los Montalvos Center for 4 months. After detecting the suspicion of dysphagia, a dysphagia-viscosity test was applied to know the tolerated textures. Then, the pharmaceutical formulations were adapted and the manipulation instructions for the drugs were indicated for their proper administration. Results: 23 out of 627 admitted patients were included, with a mean age of 85 years (σ ± 7.4). The pathologies implicated in dysphagia were: dementia (65.2%); cerebrovascular disease (30.4%), and Parkinson´s disease (4.4%). The best texture for drug intake was a "pudding" in 48.0%. 43 active ingredients were reviewed and 134 interventions were performed: in 41% of the cases, swallowing was made easier by mixing the drug with the food and in 59% water and a thickener were used. 94% of the recommendations were considered to be appropriate. Conclusion: the adaptation of the pharmaceutical formulations to the degree of dysphagia impacts on the improvement of healthcare quality by implementing safety in drug prescription and administration processes (AU)